291 related articles for article (PubMed ID: 33734167)
1. Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070).
Suzuki K; Castelli M; Komaroff M; Starling B; Terahara T; Citrome L
J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):286-294. PubMed ID: 33734167
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study.
Citrome L; Walling DP; Zeni CM; Starling BR; Terahara T; Kuriki M; Park AS; Komaroff M
J Clin Psychiatry; 2020 Dec; 82(1):. PubMed ID: 33326711
[TBL] [Abstract][Full Text] [Related]
3. Asenapine pharmacokinetics and tolerability in a pediatric population.
Dogterom P; Riesenberg R; de Greef R; Dennie J; Johnson M; Pilla Reddy V; Miltenburg AM; Findling RL; Jakate A; Carrothers TJ; Troyer MD
Drug Des Devel Ther; 2018; 12():2677-2693. PubMed ID: 30214156
[TBL] [Abstract][Full Text] [Related]
4. Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects.
Gerrits M; de Greef R; Peeters P
Biopharm Drug Dispos; 2010 Jul; 31(5-6):351-7. PubMed ID: 20549835
[TBL] [Abstract][Full Text] [Related]
5. Asenapine Transdermal Patch for the Management of Schizophrenia.
Zhou M; Derakhshanian S; Rath A; Bertrand S; DeGraw C; Barlow R; Menard A; Kaye AM; Hasoon J; Cornett EM; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2020 Sep; 50(4):60-82. PubMed ID: 33012873
[TBL] [Abstract][Full Text] [Related]
6. Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations.
Gerrits MG; de Greef R; Dogterom P; Peeters PA
J Clin Pharmacol; 2012 May; 52(5):757-65. PubMed ID: 21628604
[TBL] [Abstract][Full Text] [Related]
7. Design of long acting invasomal nanovesicles for improved transdermal permeation and bioavailability of asenapine maleate for the chronic treatment of schizophrenia.
El-Tokhy FS; Abdel-Mottaleb MMA; El-Ghany EA; Geneidi AS
Int J Pharm; 2021 Oct; 608():121080. PubMed ID: 34506923
[TBL] [Abstract][Full Text] [Related]
8. The effect of food on the high clearance drug asenapine after sublingual administration to healthy male volunteers.
Dogterom P; de Greef R; Peeters PA
Eur J Clin Pharmacol; 2015 Jan; 71(1):65-74. PubMed ID: 25552402
[TBL] [Abstract][Full Text] [Related]
9. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia.
Boulton DW; Kollia G; Mallikaarjun S; Komoroski B; Sharma A; Kovalick LJ; Reeves RA
Clin Pharmacokinet; 2008; 47(7):475-85. PubMed ID: 18563956
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers.
Willsie SK; Evashenk MA; Hamel LG; Hwang SS; Chiang YK; Palmer PP
Clin Ther; 2015 Jan; 37(1):145-55. PubMed ID: 25544247
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study.
Parikh N; Goskonda V; Chavan A; Dillaha L
Clin Drug Investig; 2013 Jun; 33(6):391-400. PubMed ID: 23605506
[TBL] [Abstract][Full Text] [Related]
13. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies.
Elshoff JP; Braun M; Andreas JO; Middle M; Cawello W
Clin Ther; 2012 Apr; 34(4):966-78. PubMed ID: 22401642
[TBL] [Abstract][Full Text] [Related]
14. The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study.
Walling DP; Hassman HA; Anta L; Ochoa L; Ayani I; Martínez J; Gutierro I
Drug Des Devel Ther; 2021; 15():4371-4382. PubMed ID: 34703212
[TBL] [Abstract][Full Text] [Related]
15. Development and Optimization of Asenapine Sublingual Film Using QbD Approach.
Dalal R; Shah J; Gorain B; Choudhury H; Jacob S; Mehta TA; Shah H; Nair AB
AAPS PharmSciTech; 2021 Oct; 22(7):244. PubMed ID: 34608546
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies.
Darwish M; Kirby M; Hellriegel ET; Yang R; Robertson P
Clin Drug Investig; 2009; 29(2):87-100. PubMed ID: 19133704
[TBL] [Abstract][Full Text] [Related]
17. Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis.
Dubovsky SL; Frobose C; Phiri P; de Greef R; Panagides J
Int J Geriatr Psychiatry; 2012 May; 27(5):472-82. PubMed ID: 21755540
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
19. Asenapine: an atypical antipsychotic with atypical formulations.
Musselman M; Faden J; Citrome L
Ther Adv Psychopharmacol; 2021; 11():20451253211035269. PubMed ID: 34540197
[TBL] [Abstract][Full Text] [Related]
20. Transdermal Asenapine in Schizophrenia: A Systematic Review.
Carrithers B; El-Mallakh RS
Patient Prefer Adherence; 2020; 14():1541-1551. PubMed ID: 32943849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
